XML 20 R10.htm IDEA: XBRL DOCUMENT
v3.23.1

Cash, Cash Equivalents and Investments | 6 Months Ended
--- | ---
Apr. 30, 2023
Cash and Cash Equivalents [Abstract] |
Cash, Cash Equivalents and Investments | Cash, Cash Equivalents and Investments Summary of Cash, Cash Equivalents and Investments The following tables summarize our cash, cash equivalents and investments by security type:
April 30, 2023 | Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Estimated Fair Value
| (In millions)
Cash | $ | 1,429 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,429 |
Cash equivalents: |  |  |  |  |  |  |
Money market funds* | 2,309 |  |  | — |  |  | — |  |  | 2,309 |
Commercial paper, corporate bonds and medium-term notes | 850 |  |  | — |  |  | — |  |  | 850 |
Total Cash equivalents | 3,159 |  |  | — |  |  | — |  |  | 3,159 |
Total Cash and Cash equivalents | $ | 4,588 |  |  | $ | — |  |  | $ | — |  |  | $ | 4,588 |
Short-term and long-term investments: |  |  |  |  |  |  |
Bank certificates of deposit and time deposits | $ | 11 |  |  | $ | — |  |  | $ | — |  |  | $ | 11 |
U.S. Treasury and agency securities | 430 |  |  | — |  |  | 8 |  |  | 422 |
Non-U.S. government securities** | 7 |  |  | — |  |  | — |  |  | 7 |
Municipal securities | 430 |  |  | 1 |  |  | 9 |  |  | 422 |
Commercial paper, corporate bonds and medium-term notes | 572 |  |  | 1 |  |  | 13 |  |  | 560 |
Asset-backed and mortgage-backed securities | 436 |  |  | — |  |  | 13 |  |  | 423 |
Total fixed income securities | 1,886 |  |  | 2 |  |  | 43 |  |  | 1,845 |
Publicly traded equity securities | 80 |  |  | 42 |  |  | 13 |  |  | 109 |
Equity investments in privately-held companies | 510 |  |  | 78 |  |  | 8 |  |  | 580 |
Total equity investments | 590 |  |  | 120 |  |  | 21 |  |  | 689 |
Total short-term and long-term investments | $ | 2,476 |  |  | $ | 122 |  |  | $ | 64 |  |  | $ | 2,534 |
Total Cash, Cash equivalents and Investments | $ | 7,064 |  |  | $ | 122 |  |  | $ | 64 |  |  | $ | 7,122 |
_________________________ *Excludes restricted cash equivalents invested in money market funds related to deferred compensation plans **Includes Canadian provincial government debt
October 30, 2022 | Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Estimated Fair Value
| (In millions)
Cash | $ | 1,199 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,199 |
Cash equivalents: |  |  |  |  |  |  |
Money market funds* | 660 |  |  | — |  |  | — |  |  | 660 |
U.S. Treasury and agency securities | 4 |  |  | — |  |  | — |  |  | 4 |
Municipal securities | 13 |  |  | — |  |  | — |  |  | 13 |
Commercial paper, corporate bonds and medium-term notes | 119 |  |  | — |  |  | — |  |  | 119 |
Total Cash equivalents | 796 |  |  | — |  |  | — |  |  | 796 |
Total Cash and Cash equivalents | $ | 1,995 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,995 |
Short-term and long-term investments: |  |  |  |  |  |  |
Bank certificates of deposit | $ | 7 |  |  | $ | — |  |  | $ | — |  |  | $ | 7 |
U.S. Treasury and agency securities | 435 |  |  | — |  |  | 13 |  |  | 422 |
Non-U.S. government securities** | 7 |  |  | — |  |  | 1 |  |  | 6 |
Municipal securities | 389 |  |  | — |  |  | 16 |  |  | 373 |
Commercial paper, corporate bonds and medium-term notes | 595 |  |  | — |  |  | 21 |  |  | 574 |
Asset-backed and mortgage-backed securities | 432 |  |  | — |  |  | 19 |  |  | 413 |
Total fixed income securities | 1,865 |  |  | — |  |  | 70 |  |  | 1,795 |
Publicly traded equity securities | 85 |  |  | 63 |  |  | 26 |  |  | 122 |
Equity investments in privately-held companies | 567 |  |  | 86 |  |  | 4 |  |  | 649 |
Total equity investments | 652 |  |  | 149 |  |  | 30 |  |  | 771 |
Total short-term and long-term investments | $ | 2,517 |  |  | $ | 149 |  |  | $ | 100 |  |  | $ | 2,566 |
Total Cash, Cash equivalents and Investments | $ | 4,512 |  |  | $ | 149 |  |  | $ | 100 |  |  | $ | 4,561 |
_________________________ *Excludes restricted cash equivalents invested in money market funds related to deferred compensation plans **Includes Canadian provincial government debt Maturities of Investments The following table summarizes the contractual maturities of our investments as of April 30, 2023:
| Cost |  | Estimated Fair Value
| (In millions)
Due in one year or less | $ | 487 |  |  | $ | 482 |
Due after one through five years | 964 |  |  | 941 |
No single maturity date** | 1,025 |  |  | 1,111 |
Total | $ | 2,476 |  |  | $ | 2,534 |
_________________________ ** Securities with no single maturity date include publicly-traded and privately-held equity securities and asset-backed and mortgage-backed securities. Gains and Losses on Investments During the three and six months ended April 30, 2023 and May 1, 2022 gross realized gains and losses on debt investment portfolio were not material. As of April 30, 2023 and October 30, 2022, gross unrealized losses related to our debt investment portfolio were not material. We regularly review our debt investment portfolio to identify and evaluate investments that have indications of possible impairment from credit losses or other factors. Factors considered in determining whether an unrealized loss is considered to be a credit loss include: the significance of the decline in value compared to the cost basis; the financial condition; credit quality and near-term prospects of the investee; and whether it is more likely than not that we will be required to sell the security prior to recovery. Credit losses related to available-for-sale debt securities are recorded as an allowance for credit losses through interest and other income (expense), net. Any additional changes in fair value that are not related to credit losses are recognized in accumulated other comprehensive income. During the three and six months ended April 30, 2023 and May 1, 2022, we did not recognize material credit losses and the ending allowance for credit losses was not material to our debt investment portfolio. The components of gain (loss) on equity investments for the three and six months ended April 30, 2023 and May 1, 2022 were as follows:
| Three Months Ended |  | Six Months Ended
| April 30, 2023 |  | May 1, 2022 |  | April 30, 2023 |  | May 1, 2022
| (In millions)
Publicly traded equity securities |  |  |  |  |  |  |
Unrealized gain | $ | 1 |  |  | $ | 17 |  |  | $ | 19 |  |  | $ | 18 |
Unrealized loss | (11) |  |  | (2) |  |  | (27) |  |  | (10) |
Realized gain on sales | 1 |  |  | — |  |  | 1 |  |  | 2 |
Realized loss on sales | (1) |  |  | — |  |  | (2) |  |  | — |
Equity investments in privately-held companies |  |  |  |  |  |  |
Unrealized gain | 8 |  |  | 13 |  |  | 12 |  |  | 25 |
Unrealized loss | (9) |  |  | — |  |  | (11) |  |  | — |
Realized gain on sales | — |  |  | 2 |  |  | 5 |  |  | 2 |
Realized loss on sales and impairment | (117) |  |  | — |  |  | (117) |  |  | (4) |
Total gain (loss) on equity investments, net | $ | (128) |  |  | $ | 30 |  |  | $ | (120) |  |  | $ | 33 |
Realized loss on sales and impairment included impairment losses on equity investments in privately-held companies of $117 million during the three and six months ended April 30, 2023. Impairment losses on equity investments were not material during the three and six months ended May 1, 2022. These impairment losses are included in interest and other income (expense), net in the Consolidated Condensed Statement of Operations.

X
- References No definition available. + Details
Name: | us-gaap_CashAndCashEquivalentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment. + References No definition available. + Details
Name: | us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration